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Abstract There has been a recent interest in using IL-15
to enhance antitumor activity in several models because
of its ability to stimulate CD8+ T cell expansion, inhibit
apoptosis and promote memory T cell survival and
maintenance. Previously, we reported that C6VL tumor
lysate-pulsed dendritic cell vaccines significantly en-
hanced the survival of tumor-bearing mice by stimulat-
ing a potent tumor-specific CD8+ T cell response. In
this study, we determined whether IL-15 used as
immunologic adjuvant would augment vaccine-primed
CD8+ T cell immunity against C6VL and further im-
prove the survival of tumor-bearing mice. We report
that IL-15 given after C6VL lysate-pulsed dendritic cell
vaccines stimulated local and systemic expansion of NK,
NKT and CD8+ CD44hi T cells. IL-15 did not, how-
ever, augment innate or cellular responses against the
tumor. T cells from mice infused with IL-15 following
vaccination did not secrete increased levels of tumor-
specific TNF-a or IFN-c or have enhanced C6VL-spe-
cific CTL activity compared to T cells from recipients of
the vaccine alone. Lastly, IL-15 did not enhance the
survival of tumor-bearing vaccinated mice. Thus, while
activated- and memory-phenotype CD8+ T cells were
dramatically expanded by IL-15 infusion, vaccine-
primed CD8+ T cells specific for C6VL were not sig-
nificantly expanded. This is the first account of using IL-
15 as an adjuvant in a therapeutic model of active
immunotherapy where there was not a preexisting pool
of tumor-specific CD8+ T cells. Our results contrast the
recent studies where IL-15 was successfully used to
augment tumor-reactivity of adoptively transferred
transgenic CD8+ T cells. This suggests that the adjuvant
potential of IL-15 may be greatest in settings where it
can augment the number and activity of preexisting tu-
mor-specific CD8+ T cells.
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lysate Æ MBL-2-DC: DC pulsed with MBL
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Introduction
Interleukin-15 was identified and purified based on its
abilities to bind the IL-2 receptor b-chain and to stim-
ulate the proliferation of IL-2-dependent cell lines and
antigen-specific T cell clones, including cytolytic effector
cells [11]. It has since been shown that while IL-2 and IL-
15 share many functions, especially in innate immunity,
they can play distinct and contrasting roles in T cell-
mediated immune responses [40]. While systemic
administration of IL-2 can act as a potent adjuvant to
tumor vaccinations and adoptive T cell transfer immu-
notherapy strategies [1, 34], it also limits the magnitude
and duration of T cell responses through elimination or
suppression of responding T cells [23, 41] and interfer-
ence with CD8+ memory T cells survival [21, 46]. High
dose IL-2 can also cause severe, dose-limiting toxicities
in patients [39]. In contrast, IL-15 rescues T cells from
IL-2-mediated activation-induced cell death [23] and
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promotes memory cell generation and maintenance [2, 4,
13, 32, 46]. IL-15 is also essential for the development
and activation of NK and NKT cells in vitro [8, 15]. In
murine tumor models, IL-15 exhibits a superior thera-
peutic index [26] and a stronger target-specific accumu-
lation with more rapid clearance from the circulation
[20] compared to IL-2. Thus, IL-15 may be an attractive
alternative to IL-2 for adjuvant use in immunotherapy.
Three primary goals in the generation of effective
immunotherapeutic approaches for tumors are to induce
effective tumor-specific cell-mediated responses, promote
the survival of antigen-specific T cells, and to induce long-
lived T cell memory against the tumor [5]. There are few
published reports assessing the effects of IL-15 on CD8+
T cell responses in vivo [7, 16, 43, 46]. However, collective
in vitro and in vivo evidence from various groups suggests
that IL-15 positively influences the initiation, clonal
expansion, contraction and maintenance phases of anti-
gen-specific CD8+T cell immunity [38]. Two groups have
recently reported the use of IL-15 in adoptive transfer
models of tumor therapy. Brentjens et al. [3] showed that
genetically targeted T cells expanded in IL-15 prior to
transfer uniquely persisted in tumor-bearing hosts and
cleared disseminated B cell tumors. Secondly, Klebanoff
et al. [19] demonstrated that systemic administration of
IL-15 in addition to T cell stimulation with an altered
peptide ligand following adoptive transfer of antigen-
specific transgenic CD8+ T cells improved their in vivo
tumor activity. While there have been few accounts of IL-
15 use in active immunotherapy protocols, the results
have supported the hypothesis that IL-15 has strong
adjuvant potential. IL-15 augmented the primary antigen-
specificCD8+T cell responsewhen delivered systemically
following peptide-pulsed dendritic cell (DC) vaccine [35],
and stimulated long-livedmemoryCD8+ responses when
delivered in a vaccinia vector with an HIV antigen [28].
However, IL-15 in combination with active immuno-
therapy against tumor has not been reported in a thera-
peutic model, where there was no preexisting pool of
tumor-reactive CD8+ T cells.
We previously demonstrated that DC pulsed with
tumor cell lysates stimulated CD8+ T cell mediated
clearance of the murine T cell lymphoma, C6VL [10],
resulting in 40% survival of tumor bearing mice. We
hypothesized that using IL-15 as an immunologic
adjuvant would augment vaccine stimulated CD8+
T cell immunity against C6VL, and result in higher
levels of survival among vaccine recipients. While IL-
15 stimulated local and systemic expansion of NK,
NKT and CD8+ CD44hi CD62L+/ T cells, it did not
increase innate or cellular responses against the tumor.
Mice infused with IL-15 following active immunization
with C6VL lysate-pulsed DC (C6VL-DC) did not have
augmented NK lytic activity, tumor-specific secretion
of Th1-type cytokines or C6VL-specific CTL activity
compared to recipients of the vaccine alone. Corre-
spondingly, the delivery of IL-15 did not enhance the
survival of tumor-bearing vaccinated mice. Thus, while
IL-15 dramatically expanded activated- and memory-
phenotype CD8+ T cells following C6VL-DC vaccines,
vaccine-primed CD8+ T cells with specificity for C6VL
were not significantly or preferentially expanded, and
the therapeutic efficacy of DC-based vaccine therapy
was not enhanced. These results, along with reports of
success in IL-15 use with adoptive transfer tumor
therapy, suggest that IL-15 will be most useful as an
immunologic adjuvant in settings where there is a
preexisting population of tumor-specific CD8+ T cells
rather than using it to augment primary CD8+ T cell




Female C57Bl/6 mice (H-2b) were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA) at 6 weeks
of age. The animals were maintained under specific
pathogen free conditions according to the guidelines in the
Animal Component of Research Protocol implemented in
VA research centers. The mice were between 7 weeks and
9 weeks of age when vaccine protocols were initiated.
Media and cytokines
AIM-V serum-free media (Invitrogen; Carlsbad, CA,
USA) containing 50 lM 2-ME was used to generate
DC-based vaccines as described below. C6VL for tumor
challenges and all tumor lines used for in vitro assays
were grown in complete media (CM), consisting of
RPMI 1640 supplemented with 10% FBS and 50 lM 2-
ME. Murine rGM-CSF (sp. act. ‡ 5.0·106 U/mg) and
murine rIL-4 (6.1·108 U/mg) were purified from over
expressing cell lines generated in our laboratory. Human
rIL-2 (18.0·106 U/mg) was obtained from Chiron Corp.
(Emeryville, CA, USA). Human rIL-15 (2.39·108 U/mg;
endotoxin levels <2.65 EU/mg protein) was kindly
provided by Amgen Corporation (Seattle, WA, USA).
Cell lines
C6VL (H-2b) is a radiation-induced T cell thymoma of
C57Bl/Ka background and expresses TCR-ab, Thy 1.2,
CD3, CD4, and H-2Db [27]. C6VL does not express
MHC Class II or Fas [29]. MBL-2 (H-2b) is a T cell
lymphoma cell line of C57Bl/6 origin (provided by I. L.
Weissman, Stanford, CA, USA) that was used as a
control T cell lymphoma lysate and control tumor for in
vitro restimulation. YAC-1 (H-2b) is a Maloney murine
leukemia virus-induced murine T cell lymphoma line of
A/Sn origin that is susceptible to NK-mediated lysis [17,
18] and was purchased from the American Type Culture
Collection (Manassas, VA, USA).
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Antibodies
FITC-conjugated anti-CD4 (GK1.5, Rat IgG2b,j), anti-
NK1.1 (PK136, Mouse IgG2a,j), anti-CD44 (IM7, Rat
IgG2b,j), anti-CD122 (5H4, Rat IgG2a), PE-conjugated
anti-CD8b.2 (53–5.8, Rat IgG1), anti-CD4 (H129.19, Rat
IgG2a), anti-CD25 (3C7, Rat IgG2b,j), anti-CD44 (IM7,
Rat IgG2b,j), anti-CD69 (H1.2F3, Hamster IgG1), anti-
CD43 (1B11, Rat IgG2a,j), anti-CD62L (MEL-14, Rat
IgG2a,j), and biotinylated anti-CD8b.2 (53–5.8, Rat
IgG1) and anti-TCR b-chain (H57-597, Hamster IgG)
were used for phenotypic analysis (all from BD Bio-
sciences, San Diego, CA, USA). Streptavidin-PerCP-
Cy5.5, Fc block and all isotype antibody controls were
also purchased from BD Biosciences. ELC-Ig chimera
was kindly provided by Dr Timothy Springer (Harvard
University, Boston, MA, USA). PE-conjugated goat
antihuman IgG was purchased from Southern Biotech-
nology Associates (Birmingham, AL, USA).
Tumor challenge
Two days prior to tumor challenge, an aliquot of tumor
cells was thawed and cultured in CM for 48 h. The cells
were collected by centrifugation, washed and counted
using a hemocytometer. The viability of the tumor cells
prior to tumor challenge was generally >98% as
determined by trypan blue exclusion. A lethal number of
tumor cells in 500 ll HBSS was injected i.p. The LD100
for C6VL was 1,000 cells. Mice received their first vac-
cination 1 day after receiving their tumor challenge.
Groups of ten mice were used for survival analysis and
were monitored for 60 days. Survival curves were con-
structed according to the Kaplan–Meier method [14].
Statistical differences between vaccine groups was
determined using the log-rank test [30], and was signif-
icant when P<0.05.
Generation of bone marrow-derived DC
Bonemarrow cellswere flushed from the femurs and tibias
of C57BL/6 mice, depleted of erythrocytes, and cultured
for 5 days in AIM-V serum-free media containing 50 lM
2-ME and 10 ng/ml rGM-CSF and rIL-4 as previously
described [10]. Nonadherent cells were enriched for DC
using one of two methods. They were harvested by gentle
pipetting and suspended in AIM-V to a density of
5.0·106 cells/ml, overlayed over media containing 14.5%
(w/v) metrizamide [9] or resuspended in 11.5% Optiprep
(iodixanol, Sigma, St. Louis, MO, USA) in Optiprep dil-
uent (0.88 w/v NaCl, 1 mM EDTA, 0.5% w/v bovine
serumalbumin, 10 mMhepes-NaOH, pH 7.4) andplaced
under HBSS [36]. The cells were centrifuged at 600·g for
15 min and the cells at the interface collected, washed and
analyzed by flow cytometry for expression of cell surface
markers as previously described [10]. Cells from each
preparation were ‡80% positive for the co-expression of
MHC II, CD11c, CD54, CD80 and CD86 (data not
shown). The DC preparations did not have cells that ex-
pressed CD3 or CD19.
Ag pulsing of DC, Immunizations
and IL-15 administration
After purification, DCs were resuspended to
1.0·106 cells/ml in AIM-V media containing freeze-thaw
cell lysate from either C6VL or MBL-2 (control) as
previously described [10]. The DC were pulsed with ly-
sates from three tumor cells per DC. After incubating
for 18 h, the DC were collected, washed three times and
suspended in HBSS at 5.0·106 cells/ml. 5.0·105 lysate-
pulsed DC were injected s.c. in the right flank of tumor-
bearing mice every 10 days. Mice used for lymphocyte
immunophenotype analysis, CTL and cytokine secretion
assays and as lymphocyte transfer donors were immu-
nized twice. Mice monitored for survival were immu-
nized three times. 0.5 lg rhIL-15 diluted in HBSS
containing 1% naı̈ve mouse serum was administered s.c.
at the vaccine site beginning 1 day after each vaccine
and continued every 12 h for five consecutive days. Mice
that did not receive IL-15 were infused with only the
diluent on the same schedule.
Immunophenotype of DLN, CLLN and splenocytes
Eighteen hours after the last IL-15 infusion, DC vaccine
primed draining lymph node (DLN, right inguinal),
contralateral lymph node (CLLN, left inguinal) and
spleens were harvested from tumor-challenged mice
(n=6–20 per group). Tumor-challenged mice treated
with diluent or IL-15 only were included as controls.
Lymph nodes and spleens were processed separately into
single-cell suspensions and then passed through 70-lm
nylon mesh filters. Splenocytes were depleted of ery-
throcytes using Red Cell Lysis Buffer (Sigma, St. Louis,
MO,USA). Pooled DLN, CLLN and splenocyte popu-
lations from each group were washed twice with PBS
containing 0.5% mouse serum and 1.0% BSA (FACS
Buffer). 1.5–3.0·105 cells per sample were seeded in wells
of round-bottom 96-well plates and prestained with Fc
block (0.5 lg/106 cells) for 20 min on ice. Cells were
stained with FITC-(1.0 lg/106 cells), PE-(0.5 lg/
106 cells) and biotin-conjugated (1.0 lg/106 cells) anti-
bodies or isotype controls in 50 ll FACS Buffer for
30 min on ice. Following two washes in 200 ll FACS
Buffer, each sample was incubated with Streptavidin-
PerCP-Cy5.5 (0.5 lg/106 cells) for 20 min on ice to de-
tect biotinylated antibodies. The recombinant CCR7 li-
gand, ELC-Ig chimera [22], was used to detect CCR7
expression. After prestaining with Fc block, cells were
incubated with purified ELC-Ig supernatant (50 ll/
sample) for 1 h on ice followed by incubation with PE-
conjugated goat antihuman IgG (0.5 lg/106 cells) for
30 min on ice. All samples were washed three times with
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FACS buffer, fixed in 50 ll of 2% paraformaldehyde (w/
v), and analyzed by flow cytometry using a FACScan
(BD Biosciences; San Jose, CA, USA) and CellQuest
software (BD Biosciences). Amorphous gates were
loosely drawn around viable cell populations based on
forward and side scatter plots to exclude cellular debris
from analysis, and 10,000 gated events were collected per
sample. In some experiments, CD8+ T cells were puri-
fied by negative selection using the MACS CD8a+ T
Cell Isolation Kit (Miltenyi Biotec; Auburn, CA, USA)
prior to staining. Flow cytometry showed that >98% of
the resulting cell population expressed CD8. NK cells
were defined as cells that were NK1.1+, abTCR; NKT
cells as NK1.1+, abTCR+; ab T cells as NK1.1,
abTCR+; and CD4 and CD8 T cells as CD4+ abTCR+
and CD8b+ abTCR+, respectively.
In vitro cytokine secretion assay
Draining lymph nodes and splenocytes from each treat-
ment group (n=5 per group) were collected as described
above. For each treatment group, 5.0·105 of each cell
populationwere plated in triplicate wells of a 96-well plate
with either 1.0·105 per well mitomycin-C-treated C6VL
or MBL-2, 1.0 lg/ml ConA, or with no stimulation
(media only) and incubated at 37C for 72 h (200 ll/well).
Wells containing only mitomycin-C-treated C6VL or
MBL-2 were included to control for cytokine secretion by
stimulator cells. Concentrations of IFN-c, TNF-a, IL-4
and IL-2 in the culture supernatants were assayed using
the BD Murine Th1/Th2 Cytometric Bead Array System
(Becton Dickinson, San Jose, CA, USA). A 1x standard
solution of mouse Th1/Th2 cytokines was prepared as
described in the manufacturer’s protocol. The remainder
of the assay was performed and analyzed as described by
the manufacturer, except all volumes were reduced by
one-half. The linear range of detection for each cytokine
monitored was 20–2,500 pg/ml. Data are represented as
the mean of triplicate samples ±SD. Statistics between
groups were measured using the Student’s t test, and sig-
nificance was reached when P<0.05.
In vitro detection of NK- and CTL-mediated lysis
Draining lymph nodes, spleen and peritoneal lavage cells
were harvested frommice treated with C6VL-DC, C6VL-
DC+IL-15, IL-15 or diluent 18 h following their last IL-
15 infusion and processed as described above. Cells were
restimulated in vitro for 5 days at a density of 5.0·106/ml
(1.0 ml per well in 24-well plates) with irradiated C6VL
(2000 Rad) in CM containing 20 U/ml rhIL-2. Following
restimulation, viable cells were enriched over Lympholyte
M density medium (Cedarlane Laboratories Ltd.; Horn-
by, ON, Canada) per the manufacturer’s protocol.
Duplicate samples of DLN, splenocytes and lavage cells
from each group were plated in round bottom 96-well
plates using threefold serial dilutions at a starting con-
centration of 5.0·106 cells/ml in CM. C6VL or control
MBL-2 cells were labeled for 3 min with Vybrant 3,3¢-
dioctadecyloxacarbocyanine perchlorate (DiO) Cell
Labeling Solution (Molecular Probes; Eugene, OR,USA)
per manufacturer’s protocol for nonadherent cells and
2.0·104 cells were added to each well in 100 ll CM,
resulting in effector-to-target ratios (E:T) of 50:1, 16.7:1
and 5.6:1 in a total volume of 200 ll/well. To measure
NK-mediated lysis, DLN and splenocytes from each
groupwere pooled andplated in duplicatewithout in vitro
stimulation in flat-bottom 48-well plates using fourfold
serial dilutions starting at a concentration of
8.0·106 cells/ml in 200 ll per well. 2.0·104 C6VL or NK-
susceptible YAC-1 cells that were labeled as indicated
above were added to each well in 200 ll CM, resulting in
E:T of 80:1, 20:1 and 5:1 in a total volume of 400 ll/well.
Wells containing only DiO-labeled target cells were in-
cluded as controls for spontaneous death of target cells for
both assays. The cells were incubated for 4 h (CTL lysis)
or 16 h (NK lysis; based onprotocol reported byKennedy
et al. [15]) at 37C in a 5%CO2 incubator and then 10 ll of
PI cell staining solution (BD Biosciences; San Jose, CA,
USA) was added to each sample and incubated an addi-
tional 15 min at RT protected from light. To determine
percent target cell death in each well, the percent of 7,500
gated DiO+ C6VL or MBL-2 target cells that were also
positive for PI staining was measured by flow cytometry
(FACScan, BD Biosciences, San Jose, CA, USA). The
gate to collect DiO+ target cells was set on a plot of for-
ward scatter versus DiO intensity to include viable and
deadDiO+C6VL,MBL-2 or YAC-1 cells and exclude all
effector cells. Percent lysis for each sample was calculated
as [(%death of target cells platedwith effectors)–(%death
of target cells without effector cells)].Data are represented
as themean of duplicate samples±SD. Statistics between
groupsweremeasuredusing the Student’s t test. Statistical
significance was reached when P<0.05. This flow cyto-
metric cytotoxicity assay was previously reported to be
suitable for measuring both T cell and NK-mediated cy-
totoxicity with sensitivity comparable to that observed
using the standard 51Cr release assay [31], and yields
highly reproducible results.
Transfer of draining lymphocytes from vaccine-
and IL-15-treated mice to naı̈ve recipients
Groups of 13 tumor-challenged donor mice were vacci-
nated twice with C6VL-DC or the control vaccine,
MBL-2 lysate-pulsed DC (MBL-2-DC). IL-15 was
administered following each vaccine as described above.
Groups of 11 mice vaccinated with C6VL-DC or MBL-
2-DC without IL-15 infusion were included as positive
and negative controls, respectively. Eighteen hours after
the last IL-15 infusion, DLN from each group were
harvested, pooled and prepared as described above.
DLN were mixed with 5000 C6VL cells (five times the
lethal dose, thawed for tumor challenge as above) and
injected into the peritoneum of ten naı̈ve recipient mice
423
per group. Each naı̈ve recipient received either a number
of cells equivalent to one donor’s DLN (3.2·106, C6VL-
DC and MBL-2-DC DLN; or 6.7·106, C6VL-DC+IL-
15 and MBL-2-DC+IL-15 DLN) or a number of cells
from C6VL-DC+IL-15 or MBL-2-DC+IL-15 recipient
DLN that resulted in the transfer of a number of CD8+
T cells that matched those transferred in one DLN from
C6VL-DC and MBL-2-DC donors (1.7·106 total cells or
5.9·105 CD8+, per recipient). Recipient mice were
monitored for survival for 60 days following tumor
challenge.
Results
IL-15 increases DLN, CLLN and spleen cellularity
Tumor bearing mice were immunized twice with C6VL
lysate pulsedDCwith each immunization followed by IL-
15 injections. IL-15 was delivered subcutaneously to
avoid administering IL-15 to the same site as the tumor
(i.p.) and to potentially augment the expansion and sur-
vival of vaccine-primed CD8+ T cells in the DLN. Tu-
mor-bearing mice injected with C6VL-DC, IL-15 or
diluent alone were included as controls. Eighteen hours
following the last IL-15 infusion, the draining lymph
nodes (DLN), contralateral lymph nodes (CLLN) and
spleens were harvested and analyzed. The lymphocyte
viability did not differ among treatment groups (data not
shown). C6VL-DC vaccinations alone did not signifi-
cantly increase DLN cellularity compared to untreated
(naı̈ve) tumor-bearing mice (P=0.057) (Fig. 1). How-
ever, the combination of C6VL-DC vaccinations and IL-
15 infusion (C6VL-DC+IL-15) significantly increased
the number of DLN cells, raising it nearly 3.5-fold com-
pared to C6VL-DC vaccine recipients (P=0.010). Simi-
larly, there was an increase in the number of cells isolated
from CLLN and spleens of mice treated with C6VL-
DC+IL-15 compared to C6VL-DC (P=0.05 and 0.012,
respectively), indicating that the IL-15 had a moderate
systemic, as well as a local, effect. IL-15 injections alone
increased cell numbers in the DLN and CLLN (P=0.015
and 0.045, respectively, compared to naı̈ve mice), but not
in the spleen (P=0.24).
C6VL-DC vaccines plus IL-15 synergistically
increases the absolute numbers of NK, NKT
and CD8+ T cells in DLN
The cellular composition of DLN, CLLN and spleens
from mice vaccinated and infused with IL-15 was
analyzed by flow cytometry. Subcutaneous IL-15,
alone or in combination with C6VL-DC vaccines, in-
creased the percentages of NK and CD8+ T cells in
the DLN, CLLN and spleens of mice (Table 1 and
Fig. 2a). In addition, increased percentages of NKT
and total abT cells were evident in the DLN, but not
the CLLN or the spleen (Table 1). The increase in
CD8+ T cells observed in IL-15 recipients was
accompanied by a compensatory decrease in the per-
centage of CD4+ T cells at all three sites. The effect of
IL-15 infusion on the cellular composition of the DLN
was more evident when the absolute numbers of each
population was compared. In the DLN, C6VL-
Fig. 1 Interleukin-15 infusion results in increased cell numbers in
the DLN, CLLN and spleen. Mice bearing a lethal number of
C6VL cells (i.p.) were vaccinated twice s.c. with 5.0·105 C6VL-DC
or HBSS (control). 0.5 lg rhIL-15 was administered s.c. at the
vaccine site every 12 h for 5 days following each vaccination. Mice
not receiving IL-15 were infused with only the diluent. Eighteen
hours following the last infusion, DLN, CLLN and spleens were
harvested from mice and viable cells enumerated. Bars represent
the average number of cells (·106) isolated per DLN, CLLN or
spleen (n=3–10 mice/group) in 2 (CLLN) or 4 (DLN and spleen)
independent experiments ± SD. P-values were calculated using a
2-sample Student’s t-test (*P<0.012; **P=0.015, #,##P<0.05)
Table 1 S.c. IL-15 has local and systemic effects on the cellular
compostion of the DLN, CLLN and spleens of recipient micea
Treatment NK NKTb abTb CD4+b CD8+b
DLN:
Naı̈ve 0.60 1.03 54.5 27.0 28.9
C6VL-DC 0.57 0.99 50.5 24.0 23.8
C6VL-DC+IL-15 1.37 2.42 60.9 18.7 38.6
IL-15 only 1.21 2.17 60.1 19.8 38.3
CLLN:
Naı̈ve 0.60 1.03 60.0 27.0 28.9
C6VL-DC 0.67 1.28 66.3 35.0 31.6
C6VL-DC+IL-15 1.01 1.12 69.5 25.8 41.8
IL-15 only 0.91 0.73 66.6 26.2 42.7
Spleen:
Naı̈ve 3.12 1.46 52.2 25.6 23.0
C6VL-DC 3.37 2.02 48.7 23.7 21.5
C6VL-DC+IL-15 5.60 2.02 50.3 15.4 30.1
IL-15 only 3.66 1.84 48.5 16.2 27.4
aCells were obtained from DLN, CLLN and spleens of mice in each
treatment group 1d following the last IL-15 infusion, and analyzed
by flow cytometry as described in Materials and methods. Numbers
indicate the average percent of total cells in replicate samples. Data
shown is representative of 4 independent experiments of n=5–6/
group
bCell populations categorized based on marker staining as indi-
cated in Materials and methods
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DC+IL-15 treatment resulted in a 8.0-fold increase in
NK, 7.1-fold increase in NKT, and a 3.6-fold increase
in abT cells per DLN compared to recipients of the
C6VL-DC vaccine alone (Fig. 2b). In addition, CD4+
and CD8+ T cell numbers were 2.3- and 4.8-fold
higher, respectively, in recipients of C6VL-DC+IL-15
compared to recipients of the C6VL-DC vaccine alone
(Fig. 2c). C6VL-DC+IL-15 treatment stimulated less
dramatic increases in NK, NKT, abT cell, and CD8+
T cell numbers in the CLLN (2.7-, 1.8-, 2.1-, and 2.7-
fold increases, respectively) and spleens (1.9-, 1.2-, 1.2-,
and 1.6-fold increases) compared to the DLN (data
not shown). IL-15 infusions without concomitant
C6VL-DC vaccination resulted in intermediate in-
creases in each cell population compared to recipients
of both treatments. Despite varying magnitudes of
CD8+ T cell expansion among the DLN, CLLN and
spleen, however, IL-15 infusion with or without con-
comitant C6VL-DC vaccination resulted in a decreased
CD4+:CD8+ T cell ratio at each site, with ratios
ranging from 0.48–0.61 compared to 1.0–1.1 in naı̈ve
mice or mice treated with C6VL-DC vaccines alone
(Fig. 2d and data not shown).
IL-15 infusion increases numbers of activated-
or memory-phenotype CD8+ T cells in DLN
CD8+ T cells were purified from the DLN of each
treatment group by negative selection and were stained
for the activation marker, CD44, expression in combi-
nation with several other activation markers CD62L,
CD122, CCR7, CD43, and CD69, to further character-
ize the influence of IL-15 infusion on the CD8+ T cell
population in the DLN. Mice that were infused with IL-
15 alone or in conjunction with C6VL-DC vaccines had
significantly higher percents of CD8+ CD44hi cells in
their DLN compared to tumor-bearing mice that re-
ceived HBSS or C6VL-DC vaccines only (Fig. 3b left
panel), resulting in 5.8- and 7.6-fold increases in the
absolute numbers of CD8+ CD44hi T cells, respectively
(Fig. 3b, right panel). Among the CD8+ CD44hi popu-
lation, both CD62L+ and CD62L cells were expanded
(Fig. 3a, c), resulting in 2.1- and 3.2-fold increases in the
percents of CD44hi CD62L+ and CD44hi CD62L
CD8+ T cells, respectively, when mice were treated with
C6VL-DC+IL-15 compared to C6VL-DC alone. While
the CD44hi CD62L phenotype has been used to indi-
cate populations of effector CD8+ T cells, we could not
detect a concomitant decrease in CCR7 or increase in
CD43 expression to further indicate that these were in-
deed effector CD8+ T cells. In contrast, increases in
CD44hi CD122+, CD44hi CCR7+, CD44hi CD69int,
CD44hi CD25int and CD44hi CD43 CD8+ T cells were
observed upon IL-15 infusion (Fig. 3d and data not
shown), consistent with the phenotype of CD8+ central
memory T cells [22]. Expansion of these cells was greater
in recipients of both C6VL-DC vaccines and IL-15
infusion compared to recipients of either treatment
alone and occurred irrespective of the presence of tumor
in the peritoneum of recipient mice (data not shown).
The effects of IL-15 infusion on the percents of CD8+
Fig. 2 Recipients of s.c. IL-15 have increased numbers of NK,
NKT and T cells in their DLN. Tumor-bearing mice were
vaccinated twice s.c. with 5.0·105 C6VL-DC or HBSS only. Mice
were infused s.c. with IL-15 or diluent only every 12 h for 5 days
after each vaccine. Eighteen hours following the last infusion, DLN
were harvested and analyzed by flow cytometry for cell surface
expression of markers indicative of (b) NK, NKT, and ab T cells;
or (a) and (c) CD4+ and CD8+ T cell subsets as described in
Materials and methods. Average absolute numbers of each cell type
per DLN were calculated as [(percentage of total cells staining
positive · number of viable cells isolated)/ n of mice per group]. a
Representative primary flow cytometry data monitoring the
percents of CD4 and CD8 T cells in the DLN of C6VL-DC
recipients +/- IL-15. b and c Bars represent the average absolute
numbers of cell types in the DLN of each group (n=5–10 mice/
group) in four independent experiments ± SD. d Bars represent the
ratio of CD4+ to CD8+ T cells in the DLN of each group
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CD44hi cells in the CLLN and spleen were also evident
(data not shown), although the change in absolute
number of the cells was of lesser magnitude than in the
DLN.
Tumor-specific secretion of cytokines is not enhanced
by s.c. IL-15 infusion
To evaluate whether IL-15 infusions augmented tumor-
specific vaccine-primed cellular immunity or innate
clearance of C6VL, groups of 5–6 mice were immunized
twice with C6VL-DC alone or with s.c. IL-15 infusion.
Mice treated with only IL-15 or its diluent were included
as controls. Eighteen hours following the last IL-15
infusion, DLN and spleens were harvested from each
group and analyzed in vitro for C6VL-specific cytokine
release and CTL- and NK-mediated killing of C6VL.
Consistent with our previous findings [10], DLN
cells from C6VL-DC vaccinated mice secreted signifi-
cant amounts of Th1-type cytokines, TNF-a and IFN-
c compared to IL-4 (Fig. 4, left panel). The secretion
of the cytokines was tumor-specific, as their amounts
were significantly lower upon in vitro stimulation
control MBL-2 tumor. DLN lymphocytes from recip-
ients that were treated with IL-15 in conjunction with
C6VL-DC vaccines also secreted TNF-a and IFN-c at
high levels (Fig. 4, right panel). Secretion of TNF-a
and IFN-c by C6VL-DC+IL-15 DLN cells were also
significantly increased upon stimulation with C6VL
compared to MBL-2. However, addition of IL-15 to
C6VL-DC vaccine therapy did not significantly in-
crease the secretion of tumor-specific TNF-a and IFN-
c by bulk draining lymph node cells compared to
treatment of the mice with C6VL-DC alone (P values
of 0.30 and 0.062 for TNF-a and IFN-c secretion,
respectively). Similarly, while high levels of tumor-
specific TNF-a and IFN-c were secreted by spleno-
cytes from C6VL-DC+IL-15 recipients upon stimu-
lation with C6VL compared to MBL-2, the levels were
not significantly higher than those secreted by
splenocytes from recipients of C6VL-DC alone (data
not shown). Secretion of IFN-c, TNF-a and IL-4 by
DLN or splenocytes from tumor-bearing mice treated
with only IL-15 or diluent and secretion of IL-2 by
any of the groups were below the limits of detection
of the assay ( £ 20.0 pg/ml, data not shown). Simi-
larly, secretion of the cytokines by mitomycin C-trea-
ted C6VL or MBL-2 stimulator cells was not detected
(data not shown).
Fig. 3 Antigen-activated or memory-phenotype CD8+ T cells are
expanded by IL-15 infusion. Groups of 10 (+IL-15) or 20 (no IL-
15) tumor-bearing mice were vaccinated and infused with IL-15 as
indicated in the Materials and methods. Eighteen hours following
the last IL-15 injection, DLN were harvested and CD8+ T cells
purified by negative selection. The CD8+ T cells were stained for
cell surface expression of CD8b (PerCP-Cy5.5) and CD44 (FITC)
alone (b), or in combination with PE-conjugated CD62L, CD122,
or CCR7 (a–c) and analyzed by flow cytometry. Bars indicate (b)
the average (%) (left) and absolute number (right) of CD8b+
CD44hi cells per DLN in each treatment group, or c, d the
percentage of CD8b+ cells in the DLN that are both CD44hi and
CD62L+/, CD122+ or CCR7+ . P values were calculated using a
two sample Student’s t test (* and **P<0.0001)
b
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IL-15 adjuvant does not stimulate NK-mediated
clearance of C6VL or augment the tumor-specific
CTL activity stimulated by C6VL-DC vaccination
of tumor-bearing mice
Overexpression of IL-15 in tumor-bearing hosts,
expression of secretable IL-15 in tumor cells and injec-
tion of high doses of recombinant IL-15 protein have all
been reported to stimulate NK-mediated clearance of
tumors in vivo [24, 26, 44]. Culturing naı̈ve splenocytes
with 150 ng/ml rhIL-15 for 48 h resulted in LAK
activity that efficiently lysed both C6VL and MBL-2
cells in vitro, while fresh splenocytes could efficiently lyse
the NK-susceptible line, YAC-1, but not C6VL or MBL-
2 target cells (data not shown). To determine whether
the dose of IL-15 that we administered in vivo over
5 days was sufficient to generate LAK activity capable
of killing C6VL in vitro, DLN and spleens from mice
treated as described above were harvested, their cells
pooled, and their ability to lyse C6VL and YAC-1 tumor
cells was immediately assessed in a 16 h cytotoxicity
assay. Pooled effector populations from tumor-bearing
naı̈ve mice demonstrated low but significant lysis of NK-
susceptible YAC-1 targets (Fig. 5b), but were unable to
lyse C6VL (Fig. 5a) (P<0.0015, lysis of C6VL com-
pared to YAC-1). The level of YAC-1 lysis mediated by
the naı̈ve effectors was very similar to data previously
reported by Kennedy et al. [15]. As expected based on
our previous results [10], vaccination of mice with
C6VL-DC did not increase NK lysis of C6VL compared
to naı̈ve effectors. Also, IL-15 treatment alone or in
combination with C6VL-DC vaccines did not increase
ba
Fig. 5 Interleukin-15 infusions do not stimulate NK-mediated
killing of C6VL. Six tumor-bearing mice per group were vaccinated
with C6VL-DC or HBSS and infused with IL-15 as indicated in the
Materials and methods. Mice were infused s.c. with 0.5 lg rhIL-15
every 12 h for five consecutive days following each vaccine.
Eighteen hours following the last IL-15 infusion, DLN and spleens
were harvested, pooled and used immediately in an overnight CTL
assay. Specific lysis of DiO-labeled C6VL (a) and NK-susceptible
YAC-1 (b) tumor cells at E:T of 80:1, 20:1 and 5:1 were assessed by
flow cytometry following a 16-h incubation of targets with
effectors. Percent lysis was calculated as described in the Materials
and methods. Data points represent the mean of duplicate samples
±SD. Representative data from one of three independent
experiments is shown
Fig. 4 Interleukin-15 infusion does not increase vaccine-primed,
tumor-specific cytokine release by DLN cells. Groups of five mice
were vaccinated with C6VL-DC or HBSS and infused with rhIL-15
as described in Materials and methods. Eighteen hours following
the last IL-15 infusion, DLN were harvested and stimulated for
72 h in vitro with mitomycin-C-treated C6VL or control tumor
cells at a ratio of one tumor cell per five responder cells. Cytokine
concentrations in culture supernatants were measured as described
in the Materials and methods. Bars represent the mean of triplicate
samples ±SD. The dotted line represents the assays lower limit of
detection (20 pg/ml). P values were calculated using a two sample
Student’s t test. Cytokine secretion by mitomycin-C-treated tumor
cells and DLN from recipients of only IL-15 or its diluent were
below the limits of detection in all cases. Representative data from
one of three independent experiments is shown
b
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the ability of the effectors to lyse C6VL cells (Fig. 5a, all
P>0.05), indicating that the dose of IL-15 that we
administered was insufficient to generate significant
LAK activity in the DLN or spleen. Surprisingly, lysis of
YAC-1 cells was not augmented by IL-15 treatment
alone or in conjunction with C6VL-DC vaccines, despite
increased numbers of NK cells in IL-15 recipients.
C6VL-specific CTL activities in the DLN, spleens
and peritoneal cavity of treated mice was also measured.
Incubation of target cells with restimulated DLN,
splenocytes and peritoneal cells from C6VL-DC recipi-
ents resulted in high levels of killing of C6VL at all E:T
ratios (Fig. 6a, b, c). The CTL activity was specific as
MBL-2 target cells were killed at significantly lower
levels than C6VL at all ratios (P<0.0047, P<0.0047
and P<0.001 for DLN, spleen and peritoneum, re-
spectively). Likewise, cells harvested from recipients of
C6VL-DC+IL-15 lysed C6VL efficiently compared to
MBL-2 (P<0.0024, <0.0032 and <0.001 for DLN,
splenocytes and peritoneal cells, respectively). However,
despite increased numbers of activated or memory-
phenotype CD8+ T cells in mice treated with C6VL-
DC+IL-15 compared to C6VL-DC alone, killing of
C6VL tumor cells was not enhanced in mice infused with
IL-15 (Fig. 6a, b, c). In vitro stimulation with C6VL
likely gave rise to some specific CTL activity against
C6VL in the cells isolated from the control treated mice.
However, killing of C6VL by cells harvested from the
DLN, spleen and peritoneum of C6VL-DC and C6VL-
DC+IL-15 recipients remained significant compared to
the background killing of C6VL by cells in the control
groups, with P values of <0.044, <0.015 and <0.05 for
all ratios in the DLN, spleen and peritoneum, respec-
tively.
IL-15 infusion does not enhance the survival of tumor-
bearing C6VL lysate-pulsed DC vaccine recipients
Prior experiments have shown that C6VL lysate-pulsed
DC vaccines are able to stimulate a protective immune
response in mice bearing a lethal number of C6VL cells
[10]. We looked to see if IL-15 infusions would enhance
the efficacy of our C6VL-DC vaccine. Mice were tumor
challenged and immunized three times with IL-15 given
between each immunization. Mice receiving MBL-2-DC
vaccines or only IL-15 were included as control groups.
As expected, C6VL-DC vaccines significantly enhanced
the survival of tumor-bearing mice compared to mice
vaccinated with MBL-2-DC (P=0.039), with 30% of the
tumor-challenged mice surviving (Fig. 7). C6VL-DC
vaccines coupled with IL-15 also significantly enhanced
the survival of tumor-bearing mice compared to MBL-2-
DC+IL-15 recipients (P=0.039). However, IL-15
infusion in addition to C6VL-DC vaccines did not
augment the survival of mice compared to C6VL-DC
vaccines alone (P=0.72). None of the control treated
groups survived the tumor challenge confirming our in
vitro evidence that IL-15 infusion does not result in
background clearance of the C6VL tumor. Modifying
our dosing schedule to give the same 0.5 lg/mouse IL-15
every 12 h, but for five consecutive days prior to the
second and third vaccines, or for more prolonged peri-
Fig. 7 Interleukin-15 infusion does not enhance the survival of
tumor-bearing C6VL lysate-pulsed DC vaccine recipients. Naı̈ve
mice were challenged with a lethal dose of C6VL. Twenty-four
hours following tumor challenge, mice received their first vaccine of
5.0·105 C6VL or MBL-2 lysate-pulsed DC. The vaccines continued
every 10 days for three vaccines. Beginning 1d following each
vaccine and continuing every 12 h for 5 days, 0.5 lg rhIL-15 was
administered s.c. at the vaccine site. Control mice receiving DC
vaccines but not IL-15 were injected with diluent alone on the same
schedule. The mice were monitored for survival for 60 days
following tumor challenge
a b c
Fig. 6 Interleukin-15 does not augment the tumor-specific CTL
activity stimulated by C6VL-DC vaccines in tumor-bearing mice.
Six mice per group were vaccinated with C6VL-DC or HBSS and
were given IL-15 or diluent only as detailed in the Materials and
methods. Eighteen hours following the last IL-15 infusion, DLN,
splenocytes and peritoneal lavage samples were harvested and
restimulated in vitro for 5 days with one irradiated C6VL cell per
five responder cells. Specific lysis of DiO-labeled C6VL and MBL-2
(control) tumor cells by (a), DLN; (b), splenocytes; or c, peritoneal
lavage cells at E:T of 50:1, 17:1 and 5.6:1 was assessed by flow
cytometry following a 4-h incubation of targets with restimulated
effectors. Percent lysis was calculated as described in the Materials
and methods. Data points represent the mean of duplicate samples
±SD. P values were calculated using a two sample Student’s t test
at each data point. Representative data from one of two
independent experiments is shown
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ods (14 consecutive days, beginning 1 day following the
first C6VL-DC vaccine) or giving the IL-15 i.p. at lower
doses also failed to improve the efficacy of the C6VL-
DC vaccine (data not shown).
Failure of IL-15 infusion to enhance vaccine-primed
clearance of C6VL in vivo is likely not due to vaccine-
primed and IL-15 expanded cells being sequestered
in the secondary lymphoid organs
Phenotypic characterization of the CD8+ T cells in the
DLN of IL-15 recipients indicated that activated T cells
with a phenotype characteristic of central memory T
cells (TCM) comprised a significant proportion of all cells
in the draining lymph nodes of mice receiving IL-15 in
addition to the C6VL-DC vaccine (Fig. 3b). TCM home
to secondary lymphoid organs due to their high levels of
CCR7 and CD62L expression [37, 41] and lack imme-
diate inflammatory and cytotoxic function. However,
they can mediate rapid recall responses with greater
potency against viral infections and established tumors
than effector-phenotype CD8+ T cells [19, 42] when
used for adoptive immunotherapy. Further, murine
antigen-primed CD8+ T cells cultured in IL-15 resemble
TCM in phenotype and function, and thus require resti-
mulation with antigen to acquire cytolytic function [22].
Based on this information, we were concerned that
possibly C6VL-specific TCM in the DLN and peripheral
lymphoid organs were not trafficking to tumor sites
where they would be restimulated and acquire effector
function [22, 41]. It was also possible that our in vitro
CTL assay was not sensitive enough to detect IL-15
induced differences in tumor-specific CTL activity, as
the assay uses small numbers of cells per sample and the
percent of CD8+ expansion was not as dramatic as the
change in absolute numbers of cells. To address these
concerns, we performed an in vivo CTL assay to com-
pare both the C6VL-clearing capacity of an entire lymph
node-equivalent of cells and the clearing capacity of a
defined number of CD8+ T cells from C6VL-DC and
C6VL-DC+IL-15 recipient mice. DLN cells from each
group were injected i.p into mice bearing five times the
lethal dose of C6VL cells in their peritoneum. Transfer
of 3.2·106 DLN cells (equivalent to one DLN) pooled
from ten C6VL-DC vaccinated mice resulted in signifi-
cant protection of naı̈ve tumor-bearing recipient mice
compared to transfer of MBL-2-DC-primed DLN
(P=0.0022) (Fig. 8a, b). While the transfer of 1 DLN
equivalent of cells from C6VL-DC+IL-15-treated mice
(6.7·106 cells pooled from 13 mice) also resulted in sig-
nificant protection of naı̈ve recipient mice compared to
the transfer of an equal number of cells from mice
treated with MBL-2-DC+IL-15 (P<0.001), the pro-
tection was not increased compared to transfer of cells
primed with C6VL-DC alone (P>0.92) (Fig. 8a). Fur-
ther, the transfer of a CD8+ T cell-matched number of
DLN (1.7·106 total cells or 5.9·105 CD8+) primed with
C6VL-DC+IL-15 did not confer significant protection
compared to transfer of the same number of MBL-2-
DC+IL-15-primed DLN cells (P=0.146) (Fig. 8b).
Discussion
Our laboratory previously demonstrated that vaccina-
tion of tumor bearing mice with lysate-pulsed DC
stimulated potent CD8+ T cell-mediated clearance of
C6VL, and resulted in an average of 40% survival [10].
While the use of IL-15 as a vaccine adjuvant has been
reported to enhance the antitumor activity of adop-
tively transferred CD8+ T cells transgenic for tumor
antigens [19, 35], the ability of IL-15 to augment
vaccine-primed responses by endogenous wild-type
CD8+ T cells has not been assessed in a therapeutic
tumor model. We hypothesized that the administration
a
b
Fig. 8 C6VL-DC+IL-15 recipients do not have enhanced C6VL-
specific CTL activity per-DLN or per-CD8+ T cell compared to
recipients of C6VL-DC vaccines alone. Tumor-bearing donor mice
(n=13 per group) were vaccinated twice with 5.0·105 C6VL- or
MBL-2-lysate-pulsed DC and infused s.c. with 0.5 lg rhIL-15 twice
daily for 5 days following each vaccine. Mice vaccinated with
C6VL-DC or MBL-2-DC without IL-15 infusion (n=11 per group)
were control donors. Eighteen hours following the last IL-15
infusion, DLN from each group were harvested, pooled, mixed
with C6VL cells and injected into the peritoneum of ten naı̈ve
recipient mice per group. Each naı̈ve recipient received 5000 C6VL
cells and either a a number of cells equivalent to one donor’s DLN
(3.2·106, C6VL-DC and MBL-2-DC DLN; or 6.7·106, C6VL-
DC+IL-15 and MBL-2-DC+IL-15 DLN) or b a number of cells
from IL-15 recipient DLN that resulted in the transfer of a number
of CD8+ T cells that matched those transferred in 1 DLN from
C6VL-DC and MBL-2-DC donors (1.7·106 total cells or 5.9·105
CD8+ per recipient)
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of IL-15 in conjunction with C6VL-DC vaccines would
enhance vaccine-primed CD8+ T cell immunity against
C6VL and thus result in higher levels of survival in
our therapeutic model. Instead, we found that IL-15
administration neither helped nor hindered C6VL-DC-
primed T cell responses against C6VL or the survival
of tumor-bearing mice. Our collective data indicates
that while IL-15 infusion following C6VL-DC vaccines
resulted in dramatic expansion of NK, NKT and
activated CD8+ T cells at both local (DLN, Figs. 2
and 3a) and distal sites (CLLN and spleen; data not
shown), T cells with specificity for C6VL were not
significantly or preferentially expanded by the treat-
ment (Figs. 4, 6, 7, 8).
Recent studies of systemic IL-15 administration in
adoptive transfer models demonstrated that systemic
administration of IL-15 augmented the primary antigen-
specific CD8+ T cell response following a peptide-pulsed
DC vaccine [35] and potentiated the in vivo tumor
activity of antigen-specific CD8+ T cells [18]. However,
these studies monitored antigen-specific responses of
transgenic CD8+ T cells following the transfer of a
relatively large number (1.0–5.0·106) of splenocytes or
purified CD8+ T cells that were activated in vivo by
vaccination [19, 35]. Thus, the inability of IL-15 to en-
hance survival in our tumor model may be due to naı̈ve
mice having comparably few resident tumor specific
CD8+ T cells that are available for stimulation by our
DC vaccines and expansion by IL-15. Similarly, Oh et al.
[28] recently reported that IL-15 only slightly increased
the frequency of antigen specific CD8+ T cells primed
by HIV vaccine vectors in wild-type mice.
It is possible that using a different IL-15 adminis-
tration schedule, route or timing relative to the DC
vaccine may be more efficacious. Our administration of
IL-15 is similar, but not exactly the same as that re-
ported by others. Rubinstein et al. [35] reported that
one round of IL-15 infusion (0.5 lg/mouse every
12 h,·7 days) following a single vaccination with OVA
peptide-pulsed DC enhanced the primary antigen-spe-
cific response of adoptively transferred OT-1 CD8+ T
cells. We also administered 0.5 lg IL-15 every 12 h,
but for 5 days following each of two vaccines. While
many groups have reported biological activity with
0.5 lg IL-15 twice daily, doses as high as 108 lg twice
daily for 3 days have been used in other murine
models [19], with the strong caveat that many manu-
scripts published on the topic have not included the
specific activity of the recombinant IL-15 used in the
studies. We chose to deliver the IL-15 s.c. at the site of
DC vaccines instead of i.p., as has been traditionally
done. This avoids administering the IL-15 to the same
site as the tumor (i.p.) and potentially biases expansion
and survival of vaccine-primed CD8+ T cells in the
DLN. The rational for administering the IL-15 at the
vaccine site is further supported by recently published
studies by Dubois et al. [6] showing that the IL-15Ra
chain functions to cross-present IL-15 from antigen-
presenting cells to T cells. Importantly, injecting IL-15
s.c. still resulted in expansion of T cells at distal sites
in vivo, indicating that our dose was sufficient to in-
duce systemic effects. Several other schedules and
amount of IL-15 were tried in our model without any
significant improvement in vaccine efficacy.
We used recombinant human IL-15 in our studies, as
many groups studying the in vivo and in vitro effects of
IL-15 have done. While doing so risks raising antihuman
IL-15 antibodies in vivo, we were unable to detect IL-15-
specific antibodies by ELISA in any of the sera from 36
individual IL-15-treated mice used in three independent
experiments (assayed 10 days following the last IL-15
infusion; data not shown). Also, while IL-15 supports
the growth and survival of some human malignant T cell
lines in vitro [33, 45], culturing C6VL for 96 h in the
presence of up to 1 lg/ml IL-15 did not influence the
proliferation rate or viability of the C6VL cells (data not
shown) nor did it hasten the demise of tumor challenged
mice (Fig. 7). Finally, while it was recently noted that
IL-15 can expand de novo-induced human antigen-spe-
cific regulatory CD4+ T cells in the presence of cognate
antigen, CD25+ CD4+ T cells were not expanded by IL-
15 infusion in our studies (data not shown), nor do we
have evidence that regulatory T cells specific for C6VL
antigens are induced by vaccination against, or tumor
challenge with, C6VL (data not shown). These results
are in line with previously published data showing that
IL-15 stimulates little, if any, proliferation of murine
CD4+ T cells [46].
We did not find that IL-15 enhanced tumor specific
cytokine secretion or CTL activity in DLN, CLLN or
spleen cells harvested 6 days following the second DC
vaccine. It is possible that due to the timing of our
analysis or the in vitro assays that we used, some
CD8+ T cell responses were augmented by IL-15 and
went undetected. Others have detected augmented in
vitro CTL activity among transgenic CD8+ T cells as
early as 6 days following a single peptide-pulsed DC
vaccine when rhIL-15 was administered using the same
dose and time schedule that we used. However, they
did not assess the in vivo tumor clearing capacity of
the cells [35]. In another study using the same model,
IL-15 without concomitant DC vaccination increased
the number of antigen-reactive T cells without
improving the overall survival of the treated mice [25].
While these studies showed that IL-15 expanded early
responses of antigen-specific CD8+ T cells, Oh et al.
[28] showed that the utility of IL-15 as adjuvant for
vaccination against HIV antigens was the induction of
longer-lived CD8+ T cell immunity in vaccine recipi-
ents, suggesting that IL-15 during priming may alter
the quality rather than just the quantity of CD8+ T
cells during the immune-induction phase. As our
analysis did not correlate the immunophenotype of a
cell to its response upon restimulation by C6VL, we
cannot say what proportion of the CTL responses that
we measured were mediated by primary effector versus
early memory CD8+ T cells primed by the C6VL-DC
vaccines, or whether IL-15 infusion changed the
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amount of cytokine a single cell type secretes upon
tumor recognition. We were consistently unable to
demonstrate any augmented antitumor immune re-
sponse among mice receiving IL-15 in addition to
C6VL-DC vaccine. If any augmented responses went
undetected by our in vitro analysis, they were not of
sufficient magnitude to positively affect the survival of
C6VL-bearing mice.
Interleukin-15, indeed, has many attributes that make
it an attractive choice for use as a vaccine adjuvant to
augment CD8+ T cell responses. While our results do
not support its use to enhance a primary antitumor
immune response, it might be very effective in enhancing
recall responses or to bolster CD8+ T cell responses
following adoptive transfer of tumor-specific T cells. We
believe that further elucidation of the kinetics of CD8+
T cell primary responses and memory cell development
following vaccination against tumor antigen, and how
they are affected by the presence or absence of tumor in
vivo, will help investigators use IL-15 to its fullest
adjuvant potential in models of active immunotherapy.
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